Pfizer Faces Italian Antitrust Probe Over Xalatan Patent
Italy's antitrust watchdog has opened an investigation into whether a Pfizer Inc. unit has improperly extended patent protection for Xalatan to shield the glaucoma treatment from generic competition....To view the full article, register now.
Already a subscriber? Click here to view full article